December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

240.72 -5.15 (-2.09%)
Streaming Delayed Price Updated: 1:49 PM EDT, Sep 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research ↗
The European Food Safety Authority (EFSA) is asking for more research on the effects of CBD on humans. 
Via Benzinga
News headline image
North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization? ↗
The North Carolina House passed Senate Bill 448, legalizing FDA-approved THC medications in a 92-9 vote, reported The Carolina Journal. 
Via Benzinga
News headline image
Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate ↗
 
Via Benzinga
News headline image
Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals ↗
The Food and Drug Administration (FDA) sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals. Companies being warned are Haniel... 
Via Benzinga
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,... 
Via FinancialNewsMedia
News headline image
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating ↗
Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
News headline image
Jazz Pharmaceuticals's Return On Capital Employed Insights ↗
Pulled from Benzinga Pro data, Jazz Pharmaceuticals (NASDAQ:JAZZ) posted Q1 earnings of $1.65 million, an increase from Q4 of 104.66%. Sales dropped to $813.72 million, a 9.26% decrease between... 
Via Benzinga
News headline image
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval? ↗
Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218. 
Via Benzinga
News headline image
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next? ↗
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S. 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY ↗
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022. 
Via Benzinga
News headline image
Jazz Pharmaceuticals: Q1 Earnings Insights ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End ↗
Miguel Martin, CEO of Aurora Cannabis Inc (NASDAQ: ACB), discussed growing Aurora into the leader of the international medical cannabis market at the Benzinga Cannabis Capital Conference on Wednesday. 
Via Benzinga
News headline image
Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent ↗
The company agreed to the FDA's post-marketing requirements for a depression drug. 
Via Investor's Business Daily
News headline image
Avicanna's Cannabinoid Drugs To Reach Brazil Via Its First 'Big Pharma' Deal ↗
 
Via Benzinga
News headline image
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies ↗
Syros Pharmaceuticals Inc (NASDAQ: SYRS)  
Via Benzinga
News headline image
Expert Ratings For Jazz Pharmaceuticals ↗
Over the past 3 months, 4 analysts have published their opinion on Jazz Pharmaceuticals (NASDAQ:JAZZ) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Wednesday ↗
Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Why Axsome Therapeutics Stock Is Trading Higher ↗
Axsome Therapeutics Inc (NASDAQ: AXSM) is trading higher Monday morning after the company announced it will acquire Sunosi from Jazz Therapeutics PLC (NASDAQ: JAZZ). 
Via Benzinga
News headline image
Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its Neuroscience Portfolio ↗
Axsome Therapeutics Inc (NASDAQ: AXSM) has  
Via Benzinga
News headline image
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Jazz Pharmaceuticals's Return On Capital Employed Insights ↗
According to data from Benzinga Pro, during Q4, Jazz Pharmaceuticals's (NASDAQ:JAZZ) reported sales totaled $896.73 million. Despite a 33.09% increase in earnings, the company... 
Via Benzinga
News headline image
Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma ↗
The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant C... 
Via Benzinga
News headline image
Expert Ratings For Jazz Pharmaceuticals ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.